Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell lines.

Efforts to improve upon the physical properties and metabolic stability of Aurora kinase inhibitor 14a revealed that potency against multidrug-resistant cell lines was compromised by increased polarity. Despite its high in vitro metabolic intrinsic clearance, 23r (AMG 900) showed acceptable pharmacokinetic properties and robust pharmacodynamic activity. Projecting from in vitro data to in vivo target coverage was not practical due to disjunctions between enzyme and cell data, complex and apparently contradictory indicators of binding kinetics, and unmeasurable free fraction in plasma. In contrast, it was straightforward to relate pharmacokinetics to pharmacodynamics and efficacy by following the time above a threshold concentration. On the basis of its oral route of administration, a selectivity profile that favors Aurora-driven pharmacology and its activity against multidrug-resistant cell lines, 23r was identified as a potential best-in-class Aurora kinase inhibitor. In phase 1 dose expansion studies with G-CSF support, 23r has shown promising single agent activity.

[1]  Connie Y. C. Ma,et al.  AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues , 2014, Journal of Translational Medicine.

[2]  J. Desai,et al.  7LBA Phase 1 dose-expansion study of AMG 900, a pan-Aurora kinase inhibitor, in adult patients with advanced taxane-resistant solid tumors , 2014 .

[3]  Xingrong Liu,et al.  Rational use of plasma protein and tissue binding data in drug design. , 2014, Journal of medicinal chemistry.

[4]  C. Rudin,et al.  Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer , 2014, Cancer medicine.

[5]  T. Bush,et al.  AMG 900, a Small-Molecule Inhibitor of Aurora Kinases, Potentiates the Activity of Microtubule-Targeting Agents in Human Metastatic Breast Cancer Models , 2013, Molecular Cancer Therapeutics.

[6]  Gregory W. Kauffman,et al.  Evaluating the differences in cycloalkyl ether metabolism using the design parameter "lipophilic metabolism efficiency" (LipMetE) and a matched molecular pairs analysis. , 2013, Journal of medicinal chemistry.

[7]  K. Glaser,et al.  Preclinical Characterization of ABT-348, a Kinase Inhibitor Targeting the Aurora, Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor, and Src Kinase Families , 2012, Journal of Pharmacology and Experimental Therapeutics.

[8]  Stephanie D. Geuns-Meyer,et al.  Synthesis of 4-substituted chlorophthalazines, dihydrobenzoazepinediones, 2-pyrazolylbenzoic acid, and 2-pyrazolylbenzohydrazide via 3-substituted 3-hydroxyisoindolin-1-ones. , 2012, The Journal of organic chemistry.

[9]  D. Zheleva,et al.  Aurora kinase inhibitors: Progress towards the clinic , 2012, Investigational New Drugs.

[10]  Rachel E. Gershman,et al.  Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays , 2011, Clinical Cancer Research.

[11]  G. Szakács,et al.  The controversial role of ABC transporters in clinical oncology. , 2011, Essays in biochemistry.

[12]  L. Berry,et al.  In vitro and in vivo pharmacokinetic characterizations of AMG 900, an orally bioavailable small molecule inhibitor of aurora kinases , 2011, Xenobiotica; the fate of foreign compounds in biological systems.

[13]  M. Radi,et al.  New insights into small‐molecule inhibitors of Bcr‐Abl , 2011, Medicinal research reviews.

[14]  T. Denny,et al.  ENMD-2076 Is an Orally Active Kinase Inhibitor with Antiangiogenic and Antiproliferative Mechanisms of Action , 2010, Molecular Cancer Therapeutics.

[15]  T. Bush,et al.  Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. , 2010, Cancer research.

[16]  R. Medema,et al.  Shared and separate functions of polo-like kinases and aurora kinases in cancer , 2010, Nature Reviews Cancer.

[17]  M. Bio,et al.  Practical Access to Metallo Thiophenes: Regioselective Synthesis of 2,4-Disubstituted Thiophenes , 2010 .

[18]  G. Shapiro,et al.  Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor, in Patients with Advanced Solid Tumors , 2010, Clinical Cancer Research.

[19]  P. Gallant,et al.  Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor. , 2010, Journal of medicinal chemistry.

[20]  D. Lane,et al.  Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. , 2010, Journal of medicinal chemistry.

[21]  T. Thomson,et al.  Regulation of Aurora B Kinase by the Lipid Raft Protein Flotillin-1* , 2010, The Journal of Biological Chemistry.

[22]  Nicholas D. Adams,et al.  Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. , 2010, Journal of medicinal chemistry.

[23]  L. Pustilnik,et al.  PF-03814735, an Orally Bioavailable Small Molecule Aurora Kinase Inhibitor for Cancer Therapy , 2010, Molecular Cancer Therapeutics.

[24]  R. Fucini,et al.  SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo , 2010, Cancer Chemotherapy and Pharmacology.

[25]  Martin C. Müller,et al.  Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib , 2010, Haematologica.

[26]  April Chen,et al.  Relationship between Passive Permeability, Efflux, and Predictability of Clearance from In Vitro Metabolic Intrinsic Clearance , 2010, Drug Metabolism and Disposition.

[27]  T. Shimomura,et al.  MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel , 2010, Molecular Cancer Therapeutics.

[28]  A. Cervantes,et al.  Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system , 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[29]  C. Claiborne,et al.  Case Study of Aurora‐A Inhibitor MLN8054 , 2009 .

[30]  J. Schellens,et al.  Clinical experience with aurora kinase inhibitors: a review. , 2009, The oncologist.

[31]  Ramona N Plant,et al.  GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models , 2009, Molecular Cancer Therapeutics.

[32]  J. Adams,et al.  Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1. , 2009, The Biochemical journal.

[33]  J. Pollard,et al.  Discovery and development of aurora kinase inhibitors as anticancer agents. , 2009, Journal of medicinal chemistry.

[34]  V. Berdini,et al.  Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. , 2009, Journal of medicinal chemistry.

[35]  Wang Shen,et al.  Discovery of a potent and selective aurora kinase inhibitor. , 2008, Bioorganic & medicinal chemistry letters.

[36]  Paola Storici,et al.  PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer , 2007, Molecular Cancer Therapeutics.

[37]  F. Gergely,et al.  Aurora-A: the maker and breaker of spindle poles , 2007, Journal of Cell Science.

[38]  K. Koretke,et al.  Binding of TPX2 to Aurora A alters substrate and inhibitor interactions. , 2007, Biochemistry.

[39]  P. Coleman,et al.  Kinesin spindle protein (KSP) inhibitors. Part V: discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by beta-fluorination to overcome cellular efflux by P-glycoprotein. , 2007, Bioorganic & medicinal chemistry letters.

[40]  N. Keen,et al.  Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. , 2007, Journal of medicinal chemistry.

[41]  Wei Chen,et al.  Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase , 2007, Proceedings of the National Academy of Sciences.

[42]  David Powers,et al.  Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase. , 2007, Journal of medicinal chemistry.

[43]  Richard Kendall,et al.  Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor. , 2007, Journal of medicinal chemistry.

[44]  Paola Storici,et al.  1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. , 2006, Journal of medicinal chemistry.

[45]  Xin Huang,et al.  Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. , 2006, Journal of medicinal chemistry.

[46]  J. Cheetham,et al.  An Automated Screening Assay for Determination of Aqueous Equilibrium Solubility Enabling SPR Study During Drug Lead Optimization , 2005 .

[47]  Hui Yang,et al.  Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase , 2005, FEBS letters.

[48]  Hao G. Nguyen,et al.  Mechanism of Aurora-B Degradation and Its Dependency on Intact KEN and A-Boxes: Identification of an Aneuploidy-Promoting Property , 2005, Molecular and Cellular Biology.

[49]  Andrea Musacchio,et al.  Mechanism of Aurora B activation by INCENP and inhibition by hesperadin. , 2005, Molecular cell.

[50]  David Bebbington,et al.  VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo , 2004, Nature Medicine.

[51]  Richard Bayliss,et al.  Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. , 2003, Molecular cell.

[52]  Stephen S. Taylor,et al.  Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores , 2003, The Journal of cell biology.

[53]  Xiaoyang Xia,et al.  High-throughput logP measurement using parallel liquid chromatography/ultraviolet/mass spectrometry and sample-pooling. , 2002, Rapid communications in mass spectrometry : RCM.

[54]  Sean Ekins,et al.  Optimizing Higher Throughput Methods to Assess Drug-Drug Interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 In Vitro Using a Single Point IC50 , 2002, Journal of biomolecular screening.

[55]  B I Sikic,et al.  Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. , 1985, Cancer research.

[56]  V. Markovtsov,et al.  Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen , 2009, Journal of Cancer Research and Clinical Oncology.

[57]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[58]  L. Berry,et al.  An examination of IC50 and IC50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes. , 2008, Drug metabolism letters.

[59]  D. Duś,et al.  Human sarcoma cell lines MES-SA and MES-SA/Dx5 as a model for multidrug resistance modulators screening. , 2005, Anticancer research.